ERBB2 and breast carcinoma: We examined expression of DUSP2 in ERBB2-positive breast cancer samples using Kaplan-Meier Plotter [34] and found that in 207 ERBB2-positive breast cancer patients with reduced DUSP2 levels showed a decreased trend in relapse-free survival that was not significant (p = 0.15) (Figure S7).